NEKTAR THERAPEUTICS 4

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), sold 186 shares of common stock on 2026-08-18 to cover taxes related to RSU vesting.

On August 18, 2026, Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 186 shares of the company’s common stock at a weighted average price of approximately $71.98 per share, for proceeds of roughly $13,400, solely to satisfy tax withholding obligations arising from the vesting of his restricted stock units, leaving him with direct ownership of 9,570 shares after the transaction.

Filing Facts

CIK

906709

Ticker

NKTR

Form

4

Source Type

fda

Accession

0001193125-26-359588

Alert Tier

5